Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy

Noritoshi Nagaya, MD; Kenji Kangawa, PhD; Takefumi Itoh, MD; Takashi Iwase, MD;
Shinsuke Murakami, MD; Yoshinori Miyahara, MD; Takafumi Fujii, MD; Masaaki Uematsu, MD;
Hajime Ohgushi, MD; Masakazu Yamagishi, MD; Takeshi Tokudome, MD; Hidezo Mori, MD;
Kunio Miyatake, MD; Soichiro Kitamura, MD

Background—Pluripotent mesenchymal stem cells (MSCs) differentiate into a variety of cells, including cardiomyocytes and vascular endothelial cells. However, little information is available about the therapeutic potency of MSC transplantation in cases of dilated cardiomyopathy (DCM), an important cause of heart failure.

Methods and Results—We investigated whether transplanted MSCs induce myogenesis and angiogenesis and improve cardiac function in a rat model of DCM. MSCs were isolated from bone marrow aspirates of isogenic adult rats and expanded ex vivo. Cultured MSCs secreted large amounts of the angiogenic, antiapoptotic, and mitogenic factors vascular endothelial growth factor, hepatocyte growth factor, adrenomedullin, and insulin-like growth factor-1. Five weeks after immunization, MSCs or vehicle was injected into the myocardium. Some engrafted MSCs were positive for the cardiac markers desmin, cardiac troponin T, and connexin-43, whereas others formed vascular structures and were positive for von Willebrand factor or smooth muscle actin. Compared with vehicle injection, MSC transplantation significantly increased capillary density and decreased the collagen volume fraction in the myocardium, resulting in decreased left ventricular end-diastolic pressure (11 ± 1 versus 16 ± 1 mm Hg, $P<0.05$) and increased left ventricular maximum dP/dt (6767 ± 323 versus 5138 ± 280 mm Hg/s, $P<0.05$).

Conclusions—MSC transplantation improved cardiac function in a rat model of DCM, possibly through induction of myogenesis and angiogenesis, as well as by inhibition of myocardial fibrosis. The beneficial effects of MSCs might be mediated not only by their differentiation into cardiomyocytes and vascular cells but also by their ability to supply large amounts of angiogenic, antiapoptotic, and mitogenic factors. (***Circulation***. 2005;112:1128-1135.)

Key Words: myocytes ■ angiogenesis ■ heart failure ■ growth substances ■ transplantation

Despite advances in medical and surgical procedures, congestive heart failure remains a leading cause of cardiovascular morbidity and mortality.[1] Idiopathic dilated cardiomyopathy (DCM), a primary myocardial disease of unknown etiology characterized by a loss of cardiomyocytes and an increase in fibroblasts, is an important cause of heart failure.[2] Although myocyte mitosis and the presence of cardiac precursor cells in adult hearts have recently been reported,[3] the death of large numbers of cardiomyocytes results in the development of heart failure. Thus, restoring lost myocardium would be desirable for the treatment of DCM.

Mesenchymal stem cells (MSCs) are pluripotent, adult stem cells residing within the bone marrow microenviron-ment.[4] In contrast to their hematopoietic counterparts, MSCs are adherent and can be expanded in culture. MSCs can differentiate not only into osteoblasts, chondrocytes, neurons, and skeletal muscle cells but also into vascular endothelial cells[5] and cardiomyocytes.[6,7] In vitro, MSCs can be induced to differentiate into beating cardiomyocytes by 5-azacytidine treatment.[8] In vivo, MSCs directly injected into an infarcted heart have been shown to induce myocardial regeneration and improve cardiac function.[9] In addition, MSC implantation induces therapeutic angiogenesis in a rat model of hindlimb ischemia through vascular endothelial growth factor (VEGF) production by MSCs.[10,11] Myocardial blood flow abnormalities, even in the presence of angiographically normal coronary arteries, have been documented in patients with DCM.[12]

Circulation is available at http://www.circulationaha.org　　　　DOI: 10.1161/CIRCULATIONAHA.104.500447

These findings raise the possibility that transplanted MSCs have beneficial effects on myocardial structure and function via myogenesis and angiogenesis. However, little information is available about the therapeutic potential of MSCs for DCM.

A unique model of myocarditis in the rat has been created by immunization with porcine cardiac myosin,[13] which results in severe heart failure characterized by increased cardiac fibrosis and left ventricular (LV) dilation.[14] Thus, the late phase of this model can serve as a model of DCM.

The purpose of this study was to investigate the following topics: (1) whether transplantation of MSCs induces myogenesis and angiogenesis, decreases collagen deposition in the myocardium, and thereby improves cardiac function in a rat model of DCM and (2) whether the beneficial effects of MSCs are mediated by their differentiation into cardiomyocytes and vascular cells and/or by their supplying angiogenic, antiapoptotic, and mitogenic factors.

Methods

Expansion of Bone Marrow MSCs
MSC expansion was performed according to previously described methods.[4] In brief, we humanely killed male Lewis rats and harvested bone marrow by flushing their femoral and tibial cavities with phosphate-buffered saline (PBS). Bone marrow cells were cultured in α-minimal essential medium supplemented with 10% fetal bovine serum and antibiotics. A small number of cells developed visible symmetric colonies by days 5 to 7. Nonadherent hematopoietic cells were removed, and the medium was replaced. The adherent, spindle-shaped MSC population expanded to $>5\times10^7$ cells within $\approx$4 to 5 passages after the cells were first plated.

Flow Cytometry
Cultured MSCs were analyzed by fluorescence-activated cell sorting (FACS) (FACScan flow cytometer, Becton Dickinson). Cells were incubated with fluorescein isothiocyanate (FITC)–conjugated mouse monoclonal antibodies against rat CD31 (clone TLD-3A12, Becton Dickinson), CD34 (clone ICO-115, Santa Cruz), CD45 (clone OX-1, Becton Dickinson), CD90 (clone OX-7, Becton Dickinson), vimentin (clone V9, Dako), and smooth muscle actin (SMA; clone 1A4, Dako). FITC-conjugated hamster anti-rat CD29 monoclonal antibody (clone Ha2/5, Becton Dickinson) and rabbit anti-rat c-Kit polyclonal antibody (clone C-19, Santa Cruz) were used. Isotype-identical antibodies served as controls.

Model of DCM
Male Lewis rats weighing 220 to 250 g (Japan SLC Inc, Hamamatsu, Japan) were used in this study. These isogenic rats served as donors and recipients of MSCs to simulate autologous implantation. DCM was produced by inducing experimental myocarditis, as described previously.[13,14] In brief, 1 mg (0.1 mL) of porcine heart myosin (Sigma) was mixed with an equal volume of Freund's complete adjuvant (Sigma) and injected into a footpad on days 1 and 7. Five weeks after immunization, these rats served as a model of heart failure due to DCM.

MSC Transplantation
In a preliminary experiment, we performed dose-response studies to obtain the maximal effects of cell transplantation. Because the effect of 10^6 MSCs was modest, we used 5×10^6 MSCs for transplantation. Five weeks after immunization, we injected a total of 5×10^6 MSCs/100 μL PBS, or PBS alone, into the myocardium at 10 points. In brief, the LV was divided into 3 levels (basal, middle, and apical). The basal and middle levels were each subdivided into 4 segments, and the apical level was subdivided into 2 segments. Injection into

each segment was performed with a 27-gauge needle. Sham rats received intramyocardial injections of 100 μL PBS. This protocol resulted in the creation of 3 groups: DCM rats given MSCs (MSC-treated DCM group, n=10); DCM rats given PBS (untreated DCM group, n=10); and sham rats given PBS (sham group, n=10). The Animal Care Committee of the National Cardiovascular Center approved this experimental protocol.

Echocardiographic Studies
Echocardiographic studies were performed by an investigator, blinded to treatment allocation, at 5 weeks after immunization (before treatment) and 4 weeks after cell transplantation (after treatment). Two-dimensional, targeted M-mode tracings were obtained at the level of the papillary muscles with an echocardiographic system equipped with a 7.5-MHz transducer (HP Sonos 5500, Hewlett-Packard).[15] LV dimensions were measured according to the American Society for Echocardiology leading-edge method from at least 3 consecutive cardiac cycles. Fractional shortening was calculated as (LVDd−LVDs)/LVDd×100, where LVDd=LV diastolic dimension and LVDs=LV systolic dimension.

Hemodynamic Studies
Hemodynamic studies were performed 4 weeks after cell transplantation. A 1.5F micromanometer-tipped catheter (Millar Instruments) was inserted into the right carotid artery for measurement of mean arterial pressure.[16] Next, the catheter was advanced into the LV for measurement of LV pressure. Hemodynamic variables were measured with a pressure transducer (model P23 ID, Gould) connected to a polygraph. After completion of these measurements, the left and right ventricles were excised and weighed.

Histological Examination
To detect fibrosis in cardiac muscle, the LV myocardium (n=5 from each group) was fixed in 10% formalin, cut transversely, embedded in paraffin, and stained with Masson's trichrome. Transverse sections were randomly obtained from the 3 levels (basal, middle, and apical), and 20 randomly selected fields per section (n=60 per animal) were analyzed. After each field was scanned and computerized with a digital image analyzer (WinRoof, Mitani Co), collagen volume fraction was calculated as the sum of all areas containing connective tissue divided by the total area of the image.[15]

To detect capillaries in the myocardium, samples of harvested muscle (n=5 each) were embedded in OCT compound (Miles Scientific), snap-frozen in LN_2, cut into transverse sections, and stained for alkaline phosphatase by an indoxyltetrazolium method. Transverse sections were randomly obtained from the 3 levels (basal, middle, and apical), and 5 randomly selected fields per section (n=15 per animal) were analyzed. The number of capillaries was counted by light microscopy at a magnification of $\times200$. The number of capillaries in each field was averaged and expressed as the number of capillary vessels. These morphometric studies were performed by 2 examiners who were blinded to treatment assignment.

Assessment of Cell Differentiation
Suspended MSCs were labeled with fluorescent dyes with use of a PKH26 red fluorescent cell linker kit (Sigma), as reported previously.[17] Fluorescence-labeled MSCs were injected into the myocardium 5 weeks after immunization. Rats (n=5) were humanely killed 4 weeks after cell transplantation. LV samples were embedded in OCT compound, snap-frozen in LN_2, and cut into sections. Immunofluorescence staining was performed with monoclonal mouse anti-cardiac troponin T (Novo), anti-desmin (Dako), anti-connexin-43 (Sigma), polyclonal rabbit anti–von Willebrand factor (Dako), and monoclonal mouse SMA (Dako). FITC-conjugated IgG antibody (BD Pharmingen) was used as a secondary antibody. To perform quantitative analysis of the magnitude of MSC differentiation into cardiomyocytes, heart cells from each rat (n=5) were isolated by incubation in balanced salt solution containing 0.06% collagenase type II (Worthington Biochemical Co), as reported previously.[18] PKH26/troponin T double-positive cells were detected by FACS.

Figure 1. Flow-cytometric analysis of the adherent, spindle-shaped MSC population expanded to 4 to 5 passages. Most of the MSCs expressed CD29 and CD90, whereas they were negative for CD31, CD34, CD45, and SMA. Some of the cells were positive for c-Kit and vimentin.

Western Blot Analysis of Matrix Metalloproteinases

To identify the protein expression of matrix metalloproteinases (MMPs)-2 and -9, Western blotting was performed with rabbit polyclonal antibody raised against MMP-2 (Laboratory vision Co) and MMP-9 (Chemicon Co). The LV obtained from individual rats was used for comparison among the 3 groups (n=5 each). These samples were homogenized on ice in 0.1% Tween 20 homogenization buffer with a protease inhibitor. Then, 40 μg of protein was transferred into sample buffer, loaded on a 7.5% sodium dodecyl sulfate–polyacrylamide gel, and blotted onto a polyvinylidene fluoride membrane (Millipore Co). After being blocked for 120 minutes, the membrane was incubated with primary antibody at a dilution of 1:200. The membrane was incubated with peroxidase labeled with secondary antibody at a dilution of 1:1000. Positive protein bands were visualized with an ECL kit (Amersham) and measured by densitometry. Western blot analysis with a mouse polyclonal antibody raised against β-actin (Santa Cruz) was used as a protein loading control.

Assay for Angiogenic, Antiapoptotic, and Mitogenic Factors

To investigate whether MSCs produce angiogenic and growth factors, we measured VEGF, hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), and adrenomedullin (AM) levels in conditioned medium 24 hours after medium replacement. VEGF, HGF, and IGF-1 were measured by enzyme immunoassay (VEGF immunoassay, R&D Systems Inc; rat HGF enzyme immunoassay, Institute of Immunology Co, Ltd; and active rat IGF-1 enzyme immunoassay, Diagnostic Systems Laboratories, Inc). AM level was measured with a radioimmu-

noassay kit (Shionogi Co), as reported previously.[19] The amounts of these products produced by MSCs were compared with those produced by bone marrow–derived mononuclear cells (MNCs) because MNCs have commonly been used for regenerative therapy.[19–21] There was no significant difference in cell viability between MSCs and MNCs 24 hours after seeding (88 ± 5% versus 85 ± 4% by trypan blue solution). In vivo, circulating levels of VEGF, HGF, IGF-1, and AM were measured before and 24 hours after administration of MSCs or vehicle (n=6 from each group).

Statistical Analysis

Numerical values are expressed as mean$\pm$SEM unless otherwise indicated. Comparisons of parameters between 2 groups were made with unpaired Student t test. Comparisons of parameters among 3 groups were made with a 1-way ANOVA, followed by the Scheffe multiple-comparison test. Comparisons of changes in parameters among the 3 groups were made by a 2-way ANOVA for repeated measures, followed by the Scheffe multiple-comparison test. A value of $P<0.05$ was considered significant.

Results

Characterization of Cultured MSCs

Most cultured MSCs expressed CD29 and CD90 (Figure 1). In contrast, the majority of MSCs were negative for CD31, CD34, CD45, and SMA. Some of the MSCs expressed c-Kit and vimentin.

Figure 2. Differentiation of transplanted MSCs into cardiomyocytes. Transplanted MSCs were engrafted in the myocardium and stained for cardiac troponin T (A) and desmin (B). Engrafted MSCs also expressed connexin-43, a gap junction protein, at contact points with native cardiac myocytes (left arrow) and other transplanted cells (right arrow) (C). Magnification ×400.

Myogenesis and Angiogenesis Induced by MSCs

Red fluorescence–labeled MSCs were transplanted into the myocardium 5 weeks after immunization. Four weeks after transplantation, MSCs were engrafted into the myocardium (Figure 2). Immunofluorescence demonstrated that transplanted MSCs were positive for the cardiac markers cardiac troponin T and desmin (Figure 2). Transplanted MSCs also expressed connexin-43, a gap junction protein, at contact points with native cardiac myocytes as well as with MSCs. FACS analysis of isolated heart cells demonstrated that $8\pm1\%$ of transplanted MSCs were double-positive for PKH26 and troponin T. These results suggest that a small number of transplanted MSCs can differentiate into cardiomyocytes.

Some transplanted MSCs formed vascular structures in the myocardium and were positive for von Willebrand factor (Figure 3A). Other MSCs were positive for SMA and participated in vessel formation as mural cells (Figure 3B). Alkaline phosphatase staining of the ischemic myocardium showed marked augmentation of neovascularization in the MSC-treated DCM group (Figures 4A–4C). Quantitative analysis demonstrated that capillary density was significantly

Figure 3. Differentiation of transplanted MSCs into vascular endothelial cells and smooth muscle cells. Some of the transplanted MSCs were positive for von Willebrand factor (vWF, A) and SMA (B) and formed vascular structures (A and B). Scale bars=10 μm.

Figure 4. A–C, Representative samples of alkaline phosphatase staining of myocardium. Magnification, ×200. Scale bars=10 μm. D, Quantitative analysis of capillary density in the myocardium. Data are mean±SEM *$P<0.05$ vs untreated DCM group.

higher in the MSC-treated DCM group than in the untreated DCM group (Figure 4D).

Angiogenic, Antiapoptotic, and Mitogenic Factors Released From MSCs

After 24 hours of culture, MSCs secreted large amounts of angiogenic and antiapoptotic factors, including VEGF, HGF, and AM (Figure 5). Compared with MNCs that have commonly been used for regenerative therapy,[20–22] MSCs secreted 4-fold more VEGF and 5-fold more HGF. Similarly, MSCs secreted 6-fold more AM, an angiogenic and antiapoptotic peptide, compared with MNCs. MSCs also secreted a large amount, 10-fold greater than MNCs, of IGF-1, a growth hormone mediator for myocardial growth (Figure 5). Transplantation of MSCs significantly increased circulating VEGF (45.8 ± 1.6 to 68.5 ± 3.6 pg/mL, $P<0.05$), HGF (431.8 ± 56.6 to 517.2 ± 67.1 pg/mL, $P<0.05$), and AM (23.4 ± 0.8 to 41.2 ± 4.8 pg/mL, $P<0.05$) 24 hours after transplantation, although vehicle injection did not alter these parameters. Serum IGF-1 tended to increase after MSC transplantation (938.1 ± 151.6 to 1063.5 ± 116.9 pg/mL, $P=NS$), but this increase did not reach statistical significance.

Hemodynamic Effects of MSC Transplantation

Nine weeks after immunization, LV end-diastolic pressure showed a marked elevation in the untreated DCM group; this elevation was significantly attenuated in the MSC-treated DCM group (Figure 6A). LV maximum dP/dt was significantly lower in the untreated DCM group than in the sham group (Figure 6B). However, LV maximum dP/dt was significantly improved 4 weeks after MSC transplantation. There was no significant difference in heart rate or mean arterial pressure among the 3 groups (the Table). Echocardiographic studies demonstrated LV dysfunction and dilation

Figure 5. A–D, Angiogenic, antiapoptotic, and mitogenic factors produced by MSCs and bone marrow–derived MNCs). Compared with MNCs, MSCs secreted large amounts of VEGF, HGF, AM, and IGF-1. *$P<0.05$ vs MNCs.

in the untreated DCM group, as indicated by a decrease in percent fractional shortening and an increase in LV diastolic dimension (Figure 6C and 6D). However, MSC transplantation increased percent fractional shortening and inhibited the increase in LV diastolic dimension.

Reduction of Myocardial Fibrosis by MSC Transplantation

Masson's trichrome staining demonstrated modest myocardial fibrosis in the untreated DCM group (Figure 7A). However,

MSC transplantation significantly attenuated the development of myocardial fibrosis. Quantitative analysis also demonstrated that the collagen volume fraction in the MSC-treated DCM group was significantly smaller than that in the untreated DCM group (Figure 7B). Western blot analysis showed that myocardial contents of MMP-2 and MMP-9 in the untreated DCM were significantly increased compared with those in the sham group (Figure 7C–E). However, the increases in MMP-2 and MMP-9 levels were attenuated by MSC transplantation, although the change in MMP-9 did not reach statistical significance.

Figure 6. A and B, Effects of MSC transplantation on hemodynamic parameters. LVEDP indicates LV end-diastolic pressure; Max dP/dt, LV maximum dP/dt. Data are mean±SEM. *$P<0.05$ vs sham group; †$P<0.05$ vs untreated DCM group. C and D, Changes in echocardiographic parameters induced by MSC transplantation. %FS indicates LV fractional shortening. Data are mean±SEM *$P<0.05$ vs before transplantation; †$P<0.05$ vs the time-matched untreated DCM group.

Physiological Profiles of the 3 Experimental Groups

	Sham	Untreated DCM	MSC-Treated DCM
n	10	10	10
Body wt, g	421±8	372±4*	389±5*
LV wt/body wt, g/kg	1.91±0.05	2.18±0.06*	2.05±0.05
RV wt/body wt, g/kg	0.55±0.01	0.68±0.02*	0.60±0.03†
Heart rate, bpm	403±10	432±15	417±12
Mean arterial pressure, mm Hg	134±2	123±3	132±5

wt indicates weight; RV, right ventricle. Sham-operated rats were given vehicle only. The untreated DCM group included DCM rats treated with vehicle. The MSC-treated DCM group included DCM rats treated with MSCs. Data are mean±SEM.

*$P<0.05$ vs sham group; †$P<0.05$ vs untreated DCM group.

Discussion

In the present study, we have demonstrated the following effects of MSC transplantation in a rat model of DCM: (1) induction of myogenesis and angiogenesis; (2) differentiation of transplanted MSCs into cardiomyocytes, vascular endothelial cells, and smooth muscle cells; (3) secretion of large amounts of VEGF, HGF, AM, and IGF-1; (4) improvement of cardiac function and inhibition of ventricular remodeling; and (5) decrease in collagen volume fraction in the myocardium.

Earlier studies have shown that transplantation of MSCs improves cardiac function in experimental models of ischemic heart disease.[9,23] However, little information is available about the therapeutic potential of MSCs for chronic heart failure due to DCM. Previous studies have shown that porcine cardiac myosin-induced myocarditis progresses to a chronic phase resembling DCM.[13,14] Thus, we used this model 5 weeks after immunization as an example of experimental DCM.

In the present study, transplanted MSCs were engrafted into the myocardium in a rat model of DCM. Four weeks after transplantation, some of the engrafted MSCs were positively stained for cardiac troponin T and desmin. Transplanted MSCs also expressed connexin-43, a gap junction protein, at contact points with native cardiac myocytes as well as with MSCs. These results suggest that MSCs differentiate into cardiomyocytes in the myocardium and form connections with native cardiomyocytes in rats with DCM. Unlike earlier studies that have used a model of myocardial infarction,[7,9,23] we used a rat model of DCM to demonstrate the engraftment and cardiogenic differentiation of MSCs. Importantly, MSC transplantation improved cardiac function in these rats, as indicated by a significant decrease in LV end-diastolic pressure and an increase in LV dP/dt_{max}. Thus, the improvement in cardiac function may be a result of MSC-induced myocardial regeneration; however, further studies are necessary to investigate the mechanisms by which MSCs develop into cardiac myocyte–like cells.

Some of the transplanted MSCs were positive for a vascular endothelial cell marker and participated in vessel formation. MSC transplantation significantly increased capillary density in the myocardium. SMA staining revealed that MSCs differentiated into vascular smooth muscle cells, which play an important role in vessel maturation. Earlier studies have shown that transplantation of MNCs induces therapeutic angiogenesis in patients with limb ischemia or ischemic heart disease.[20–22] The angiogenic potential of MNCs is mediated at least in part by production by the cells of a variety of angiogenic factors.[24] Although MSCs have also been shown to produce VEGF,[10,25] there has been no study to compare their production between MSCs and MNCs. The present study demonstrated that MSCs secreted ≈4-fold more VEGF compared with MNCs. Furthermore, MSCs secreted large amounts of HGF and AM, potent angiogenic factors.[26–30] Taking these findings together, MSCs may contribute to neovascularization in the myocardium not only through their ability to generate capillary-like structures but also through growth factor–mediated paracrine regulation. Myocardial blood flow abnormalities have been documented in patients with heart failure caused by DCM.[12] Thus, it is possible that MSC-induced neovascularization contributes to improvement in cardiac function.

Figure 7. Effects of MSC transplantation on myocardial fibrosis. A, Photomicrographs show representative myocardial sections stained with Masson's trichrome. Scale bars=10 μm. B, Quantitative analysis demonstrated that the collagen volume fraction in the MSC-treated DCM group was significantly smaller than that in the untreated DCM group. C, Representative Western blots for MMPs-2 and -9 and β-actin in the heart. D and E, Quantitative analysis of cardiac tissue contents of MMP-2 and -9. Data are mean±SEM *$P<0.05$ vs sham group; †$P<0.05$ vs untreated DCM group.

HGF has not only angiogenic but also cardioprotective effects, including antiapoptotic, mitogenic, and antifibrotic activities.[26,27] *HGF* gene transfer into the myocardium improves myocardial function and geometry.[28] In particular, the antifibrotic effects of HGF through inhibition of transforming growth factor-β expression is beneficial for heart failure. Cultured MSCs secreted a large amount of HGF. In vivo, transplantation of MSCs slightly increased plasma HGF in rats. It significantly attenuated the development of myocardial fibrosis in a rat model of DCM. These results suggest that MSC-derived HGF may contribute to improvements in cardiac function partly through its antifibrotic effects.

MSCs also produced AM, a potent vasodilator and cardioprotective peptide.[29] We have shown that AM prevents cardiomyocyte apoptosis through the phosphatidylinositol 3-kinase/Akt–dependent pathway[16] and that it has potent angiogenic effects.[30] AM inhibits proliferation of cardiac fibroblasts through the cAMP-dependent pathway.[31] Administration of AM inhibits LV remodeling and improves cardiac function in heart failure.[32–34] In the present study, cultured MSCs secreted a large amount of AM in vitro. In vivo, transplantation of MSCs markedly increased plasma AM level. Taken together, these findings suggest that MSCs may exert their cardioprotective effects through AM-mediated paracrine regulation.

IGF-1, a growth hormone mediator, plays an important role in myocardial and skeletal muscle growth.[35,36] Administration of IGF-1 improves cardiac function after myocardial infarction through enhancement of myocardial growth.[37] Its protective and antiapoptotic properties have been demonstrated in different models of myocardial ischemia.[38] Furthermore, IGF-1 exerts Ca^{2+}-dependent, positive inotropic effects through a phosphatidylinositol 3-kinase–dependent pathway.[39] Interestingly, the present study demonstrated that MSCs secreted significant amounts of IGF-1 in vitro, 10-fold greater than MNCs. These findings raise the possibility that MSC-derived IGF-1 may participate in myocardial growth and enhancement of myocardial contractility in a rat model of DCM.

MMPs also play a crucial role in extracellular remodeling in heart failure.[40] In fact, pharmacological inhibition of MMP activities prevents progressive LV remodeling in an animal model of heart failure.[41] In the present study, cardiac MMP-2 and MMP-9 were increased in rats with DCM, which is consistent with recent findings in patients with heart failure.[40,42] Interestingly, MSC transplantation attenuated the increases in cardiac MMP-2 and MMP-9 in a rat model of DCM. Although the underlying mechanisms remain unclear, MSC transplantation may influence extracellular remodeling in heart failure.

The present study has some limitations. First, immunohistochemical evidence suggests differentiation of MSCs into cardiomyocytes, vascular endothelial cells, and smooth muscle cells. However, further studies are necessary to convincingly demonstrate differentiation of MSCs into a specific cell type. Second, the model of DCM used in this study was an injury model, and the effects of treatment may be related to attenuation of the injury rather than to the established cardiomyopathy. Nonetheless, the experiment was performed 5 to 9 weeks after myosin injection, by which time inflammatory changes were hardly observed and had been replaced by fibrosis.[43]

Conclusions

MSC transplantation improved cardiac function in a rat model of DCM, possibly through induction of myogenesis and angiogenesis, as well as by inhibition of myocardial fibrosis. The beneficial effects of MSCs may be mediated at least in part by their differentiation into cardiomyocytes and vascular cells and by their ability to supply large amounts of angiogenic, antiapoptotic, and mitogenic factors. Thus, MSC transplantation has potential as a new therapeutic strategy for the treatment of DCM.

Acknowledgments

References

1. Cohn JN. The management of chronic heart failure. *N Engl J Med.* 1996;335:490–498.
2. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. *N Engl J Med.* 1994;331:1564–1575.
3. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med.* 2001;344:1750–1757.
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. *Science.* 1999;284:143–147.
5. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. *J Clin Invest.* 2002;109:337–346.
6. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. *Circulation.* 2002;105:93–98.
7. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. *Nat Med.* 2003;9:1195–1201.
8. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. *J Clin Invest.* 1999;103:697–705.
9. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. *Ann Thorac Surg.* 2002;73:1919–1925.
10. Al-Khaldi A, Al-Sabti H, Galipeau J, Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. *Ann Thorac Surg.* 2003;75:204–209.
11. Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. *Gene Ther.* 2003;10:621–629.
12. Parodi O, De Maria R, Oltrona L, Testa R, Sambuceti G, Roghi A, Merli M, Belingheri L, Accinni R, Spinelli F, Pellegrini A, Baroldi G. Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. *Circulation.* 1993;88:509–522.
13. Kodama M, Zhang S, Hanawa H, Saeki M, Inomata T, Suzuki K, Koyama S, Shibata A. Effects of 15-deoxyspergualin on experimental autoimmune giant cell myocarditis of the rat. *Circulation.* 1995;91:1116–1122.
14. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hasegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. *Br J Pharmacol.* 2000;130:1489–1495.

15. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H, Kangawa K. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. *Circulation*. 2001;104:1430–1435.

16. Okumura H, Nagaya N, Itoh T, Okano I, Hino J, Mori K, Tsukamoto Y, Ishibashi-Ueda H, Miwa S, Tambara K, Toyokuni S, Yutani C, Kangawa K. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. *Circulation*. 2004;109:242–248.

17. Messina LM, Podrazik RM, Whitehill TA, Ekhterae D, Brothers TE, Wilson JM, Burkel WE, Stanley JC. Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat. *Proc Natl Acad Sci U S A*. 1992;89:12018–12022.

18. Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, Ogawa E, Igaki T, Yamashita J, Masuda I, Yoshimasa T, Tanaka I, Saito Y, Nakao K. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. *Circulation*. 1997;96:3737–3744.

19. Ohta H, Tsuji T, Asai S, Sasakura K, Teraoka H, Kitamura K, Kangawa K. A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. *Clin Chim Acta*. 1999;287:B131–B143.

20. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, Onitsuka I, Matsui K, Imaizumi T. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. *J Clin Invest*. 2000; 105:1527–1536.

21. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet*. 2002;360:427–435.

22. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. *Lancet*. 2003;4:47–49.

23. Min JY, Sullivan MF, Yang Y, Zhang JP, Converso KL, Morgan JP, Xiao YF. Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. *Ann Thorac Surg*. 2002;74:1568–1575.

24. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A, Shintani S, Murohara T, Imaizumi T, Iwasaka T. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. *Circulation*. 2001;104:1046–1052.

25. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res*. 2004;94:678–685.

26. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. *Nature*. 1989;342:440–443.

27. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. *J Clin Invest*. 2000;106:1511–1519.

28. Li Y, Takemura G, Kosai K, Yuge K, Nagano S, Esaki M, Goto K, Takahashi T, Hayakawa K, Koda M, Kawase Y, Maruyama R, Okada H, Minatoguchi S, Mizuguchi H, Fujiwara T, Fujiwara H. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. *Circulation*. 2003;107:2499–2506.

29. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. *Biochem Biophys Res Commun*. 1993;192:553–560.

30. Tokunaga N, Nagaya N, Shirai M, Tanaka E, Ishibashi-Ueda H, Harada-Shiba M, Kanda M, Ito T, Shimizu W, Tabata Y, Uematsu M, Nishigami K, Sano S, Kangawa K, Mori H. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: benefits of a novel nonviral vector, gelatin. *Circulation*. 2004;109:526–531.

31. Tsuruda T, Kato J, Kitamura K, Kawamoto M, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth. *Cardiovasc Res*. 1999;43:958–967.

32. Nishikimi T, Yoshihara F, Horinaka S, Kobayashi N, Mori Y, Tadokoro K, Akimoto K, Minamino N, Kangawa K, Matsuoka H. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. *Hypertension*. 2003;42:1034–1041.

33. Nakamura R, Kato J, Kitamura K, Onitsuka H, Imamura T, Cao Y, Marutsuka K, Asada Y, Kangawa K, Eto T. Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. *Circulation*. 2004;110:426–431.

34. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. *Circulation*. 2000;101:498–503.

35. Fuller J, Mynett JR, Sugden PH. Stimulation of cardiac protein synthesis by insulin-like growth factors. *Biochem J*. 1992;282:85–90.

36. Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. *Endocr Rev*. 1996;17:481–517.

37. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat: a combined in vivo and in vitro evaluation. *Circulation*. 1996;93:800–809.

38. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. *J Clin Invest*. 1997;100:1991–1999.

39. von Lewinski D, Voss K, Hulsmann S, Kogler H, Pieske B. Insulin-like growth factor-1 exerts Ca^{2+}-dependent positive inotropic effects in failing human myocardium. *Circ Res*. 2003;92:169–176.

40. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. *Circulation*. 1998;97:1708–1715.

41. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. *Circ Res*. 1999;85:364–376.

42. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. *Circulation*. 2000;102:1944–1949.

43. Kodama M, Matsumoto Y, Fujiwara M, Zhang SS, Hanawa H, Itoh E, Tsuda T, Izumi T, Shibata A. Characteristics of giant cells and factors related to the formation of giant cells in myocarditis. *Circ Res*. 1991;69:1042–1050.

CLINICAL PERSPECTIVE

Transplantation of stem or progenitor cells has the potential to improve and restore cardiac function. To date, experimenters investigating the possible therapeutic effects of stem cells in the heart have used models of infarction, and little information is available about the therapeutic potential of cell transplantation for heart failure due to dilated cardiomyopathy. In the present study, we demonstrated that transplantation of stem cells improved cardiac function in a model of myocarditis. We found evidence that stem cells may work to improve heart function by both myogenesis and angiogenesis while inhibiting myocardial fibrosis. Based on our data, part of the mechanism for this improvement may occur through the action of stem cells as a source of growth factors and cytokines in the heart. This study supports the overall notion that mesenchymal stem cells transplanted into the failing heart have potential as a new therapeutic strategy for the treatment of dilated cardiomyopathy.